Mild and Rapidly Improving Stroke Study

Proportion of patients with dependence or disability in activities of daily living at 90 days

Proportion of patients not independent in activities of daily living defined as a Barthel Index score \<95

Time frame: 90 days

Symptomatic intracranial hemorrhage due to Alteplase

Amongst those that receive intravenous Alteplase, a secondary safety measure is the proportion of patients that develop neurologic worsening development of symptomatic intracerebral hemorrhage, defined as neurological deterioration that, in the judgment of the investigator, is related to intracranial hemorrhage confirmed by CT or MRI, within 36 hours of administration of Alteplase.

Time frame: 36 hours

Proportion of patients not independent at 30 days

Proportion of patients with modified Rankin Scale 2-6 at 30 days.

Time frame: 30 days

Quality of life by the EuroQOL EQ-5D

EuroQOL will be treated as a continuous measure

Time frame: 90 days

Stroke disability by the Stroke-Impact Scale-16

SIS-16 will be treated as a continuous measure

Time frame: 90 days

Independence with Activities of Daily Living by the Barthel Index

BI will be treated as a continuous measure; pre specified analysis include proportion of patients with Barthel Index \<95